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Abstract
Mesenchymal stem cells (MSCs) have anti-inflammatory and immunosuppressive properties and may be useful in the
therapy of diseases such as arteriosclerosis. MSCs have some ability to traffic into inflamed tissues, however to exploit this
therapeutically their migratory mechanisms need to be elucidated. This study examines the interaction of murine MSCs
(mMSCs) with, and their migration across, murine aortic endothelial cells (MAECs), and the effects of chemokines and shear
stress. The interaction of mMSCs with MAECs was examined under physiological flow conditions. mMSCs showed lack of
interaction with MAECs under continuous flow. However, when the flow was stopped (for 10min) and then started, mMSCs
adhered and crawled on the endothelial surface, extending fine microvillous processes (filopodia). They then spread
extending pseudopodia in multiple directions. CXCL9 significantly enhanced the percentage of mMSCs adhering, crawling
and spreading and shear forces markedly stimulated crawling and spreading. CXCL9, CXCL16, CCL20 and CCL25 significantly
enhanced transendothelial migration across MAECs. The transmigrated mMSCs had down-regulated receptors CXCR3,
CXCR6, CCR6 and CCR9. This study furthers the knowledge of MSC transendothelial migration and the effects of chemokines
and shear stress which is of relevance to inflammatory diseases such as arteriosclerosis.
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Introduction
The ability of mesenchymal stem cells (MSCs) to differentiate
down several different cell lineages, as well as their anti-
inflammatory and immunologic characteristics, their lack of
ethical controversy, and their relative ease of expansion in culture
make these cells a promising source of stem cells for treatment of
many forms of inflammatory disease and injury [1]. This makes
them potentially useful as an anti-inflammatory therapy for
atherosclerosis and several reports have used cultured MSCs to
treat myocardial infarction [2–4], as well as other conditions such
as stroke or spinal cord injury [5,6], experimental autoimmune
encephalitis (EAE) [7], radiation injury [8], wounded skin [9] and
graft-versus-host disease [10]. Although site-directed delivery of
MSCs may be useful in certain settings, for example to treat non-
union fractures [11], systemic infusion of MSCs circumvents
problems associated with site-specific delivery, such as calcification
and tissue damage [12]. Furthermore, systemic delivery enables
the delivery of multiple doses, and is potentially a less invasive
procedure than site-directed delivery. In order to treat atheroscle-
rosis directly via systemic delivery, MSCs would need to traverse
the aortic endothelium and enter the tissue to exert anti-
inflammatory effects. However, the migration and engraftment
of MSCs by this route is not very efficient [13], and there is a need
to understand how MSCs extravasate from the blood into tissues
so that this recruitment may be increased to help reduce
inflammation and enhance tissue repair.
Much is known concerning the leukocyte adhesion cascade and
how these cells migrate from the circulation and into inflamed tissues
[14,15]. Leukocytes undergo a sequence of interactions at the luminal
endothelial surface including tethering, rolling, activation, arrest,
spreading and crawling, followed by transendothelial migration.
However, there is a lack of knowledge concerning MSCs, whether
they undergo similar interactions with endothelial cells and what
factors regulate their transendothelial migration. Furthermore the
influence fluid shear stress, which occurs physiologically in the
circulation,onMSC-endothelialinteractions needs to be addressed as
this has been shown to be important for leukocyte migration [16].
Chemokine receptors and their chemokine ligands are essential
components involved in the migration of leukocytes into sites of
inflammation, and we have recently demonstrated functional
expression of various chemokine receptors on murine MSCs
(mMSCs) using standard Boyden-type chambers in the absence of
endothelial cells [17]. The expression of chemokine receptors on
human MSCs have also been reported by ourselves and others
[17–22], some of which are in common with the mouse (CXCR3,
CXCR6 and CCR9). There are also numerous leukocyte adhesion
molecules known to be involved in migration of cells across the
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MSCs [23,24]. Adhesion molecule pairs that may be functionally
important in the adherence of MSCs to the endothelium are
CD44, VCAM-1 and its counterligand VLA-4, and other b1
integrins [25–28]. However, little is known about the mechanism
of MSC transendothelial migration and the role of chemokines in
driving this mechanism. Two recent studies have examined
transendothelial migration under static conditions in vitro using a
co-culture of endothelial cells and MSCs [27,29]. They both found
that when endothelial cells were stimulated with inflammatory
cytokines, MSCs showed morphological changes and integration
within the endothelial monolayer. They also found that MSCs
penetrate the endothelium via plasmic podia, and secrete MMP-2,
a basement membrane-degrading enzyme that is known to
facilitate the trafficking of haematopoietic stem cells [30].
The aim of the present study was to investigate the effect of
chemokines and shear stress on the adherence murine MSCs
(mMSCs) to murine aortic endothelial cells (MAECs). It is shown
for the first time that MSCs undergo spreading and crawling
behaviour when in contact with endothelial cells and that these are
enhanced by chemokine stimulation and shear stress. Chemokines
also enhance the transendothelial migration of mMSCs across
MAECs which results in down-regulation of chemokine receptors
on migrated cells. We have previously shown that mMSCs express
some of the same chemokine receptors as human MSCs [17] and
consequently these mMSCs would be a useful model to further
study the role of selective chemokine receptors in in vivo models of
atherosclerosis and myocardial infarction.
Methods
Isolation and Expansion of Murine MSCs
Primary mMSCs were obtained from BALB/c mice, 6–10
weeks old [17] and isolated as previously described [17,31], with
ethical approval sought from the ethics committee of the RJAH
Orthopaedic Hospital, Oswestry, UK. Briefly, marrow was
removed from the long bones and cells plated out in cell isolation
media (CIM) (RPMI-1640 (Lonza, Slough, UK) with 9% FBS, 9%
horse serum (both Gibco, Invitrogen, Paisley, UK) at 37uC, 5%
CO2. After 24 hours, non-adherent cells were removed. After 4
weeks cells were re-plated at 100 cells per cm
2 in complete
expansion media (CEM) (Iscove Modified Dulbecco Medium
(Lonza) with 9% FBS, 9% horse serum) to expand MSCs. These
cells were .95% positive for CD105, and completely negative
(0%) for CD45 and CD34 [17]. When incubated in osteogenic and
adipogenic media they were positive for alkaline phosphatase and
intracellular lipid respectively [17].
Culture of Mouse Endothelial Cells
The MAEC line was a kind gift from Dr Hiroko Inoue, Tsurumi
University School of Dental Medicine, Japan. The cell line was
established from p53-deficient mouse aortas [32]. It has an
endothelial phenotype, with Weibel-Palade bodies and endothelial
markers and adhesion molecules. Furthermore TNFa promotes
lymphocyte adhesion to MAECs, providing a model to study
inflammation and leukocyte migration in vitro. Cells were grown in
Medium 199 (Sigma, Poole, UK) with 5% FBS, 1 U/ml of heparin
sodium and 5 ng/ml of murine VEGF (Peprotech, London, UK),
at 37uC, 5% CO2. Media was changed every 3–4 days.
The brain endothelial cell line was purchased from LGC
Promochem (ATCC)(Teddington, UK) and was originally isolated
from a BALB/c mouse brain endothelioma [33,34]. The
endothelial nature of the cells was confirmed by the observed
expression of von Willebrand factor and uptake of fluorescently
labeled LDL. Other molecules expressed by endothelial cells have
been shown to be constitutively expressed by these cells, including
ICAM-1 and VCAM-1, or induced by stimulation with TNFa or
lipopolysaccharide (LPS), such as E-selectin and P-selectin. Cells
were grown in DMEM (Lonza) with added antibiotics and 10%
FBS according to the manufacturer’s instructions.
Flow Assay
MAECs were seeded into Ibidi microslides (Wolf laboratories,
Pocklington, UK) and grown to confluence, then stimulated with
murine TNFa at 100 ng/ml for 16 hours at 37uC. They were then
washed with medium and treated with or without murine CXCL9
(MIG) (100 ng/ml for 30 min)(Peprotech). The microslides were
incorporated into a flow-based adhesion assay where a syringe
pump draws liquid through the microslides at a controlled rate, at
37uC, whilst allowing visualisation of the cells inside the slide by
phase contrast microscopy [35]. Murine MSCs in serum-free
medium were perfused (1610
6/ml) through the microslides at
0.1 Pa for 4 minutes, then washed with medium at the same flow
rate for 15 minutes. Video recordings were made throughout to
analyse MSC behaviour. Murine MSCs were also added to the
microslides at 4610
6/ml and allowed to incubate at 37uC for 10
minutes, under static conditions, then serum-free medium was
perfused through at 0.1 Pa (1 dyne/cm
2) for 2 hours. Images were
recorded every 15 seconds throughout to examine interaction of
MSCs with the endothelium.
Transendothelial Chemotaxis
Transwell inserts with 8 mm pore size filters were coated with
fibronectin (from human plasma, Sigma) (4 ug/ml in PBS) and
transferred to 24-well plates treated with Sigmacote (Sigma), to
prevent the adherence of migrated cells. Approximately 4610
5
MAECs were seeded onto the filter of each transwell insert and
grown to 100% confluence over 2 days, then activated with
100 ng/ml of murine TNFa (Peprotech) in serum-free medium for
4 hours at 37uC. Three wells were left unstimulated as a control.
Murine MSCs were stained with 8 mm Calcein-AM (Molecular
Probes, Invitrogen) in PBS for 30 min at 37uC. Meanwhile,
medium with or without murine CXCL9 (MIG), CCL20 (MIP3a),
CCL25 (TECK) and CXCL16 (Peprotech) were added to
the wells of a 24-well plate, underneath the inserts, at various
concentrations. Each condition was performed in triplicate.
600,000 mMSCs were added to each of the upper wells of the
inserts, suspended in serum-free medium, and the plate incubated
at 37uC, 5% CO2 and 90% humidity overnight for 16 hours. The
number of mMSCs which had migrated through to the bottom
well was calculated using an FLX800 microplate fluorescence
reader (Bio-tek Instruments Ltd, Potton, UK), having set up a
standard curve for fluorescence versus cell number.
The amount of each chemokine used was 10 ng/ml. This was
based on initial dose response experiments (0–1000 ng/ml) using
the same murine MSCs in Boyden-type chemotaxis assays [17].
Results showed that 10 ng/ml or 100 ng/ml were the most
effective concentrations to significantly stimulate MSC migration;
lower (,10 ng/ml) or higher (.500 ng/ml) concentrations of
each chemokine did not stimulate migration [17]. Therefore in the
current transendothelial migration experiments 10 and 100 ng/ml
of chemokines were used and the former concentration was found
to be effective at stimulating MSC migration whereas the latter
produced insignificant results.
Flow Cytometry
MSCs from transendothelial chemotaxis experiments or those
detached from flasks by incubation with trypsin-EDTA were
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appropriate serum to block non-specific binding for 60 minutes at
4uC. Cells were found to be .95% viable using the trypan blue
exclusion assay. MSCs were incubated on ice for 30 minutes with
saturating amounts of the appropriate primary antibody in buffer,
washed, then stained with an appropriate biotinylated secondary
antibody for 30 minutes on ice, washed, then stained with a
streptavidin-PE labelled conjugate for 30 minutes [17]. As a
negative control, cells were also stained with the relevant isotype
control immunoglobulin (Ig) instead of primary antibody, as well
as the secondary antibody and streptavidin conjugate described.
Antibodies were anti-mouse CCR6, anti-mouse CCR9, anti-
mouse CXCR3, anti-mouse CXCR6, rat IgG2a isotype control
and rat IgG2b isotype control (all R&D Systems, Abingdon, UK),
and biotinylated anti-rat Ig and streptavidin-PE conjugate (both
BD Pharmingen, Oxford, UK). For the transendothelial chemo-
taxis experiments, the percentage of MSCs positive for each of the
chemokine receptors was determined by gating only on calcein
labelled cells in the FITC/FL1 channel, and this gating was also
used for the mean fluorescence intensity (MFI) measurements after
subtraction of the Ig control.
Statistics
For transendothelial migration of mMSCs in response to chemo-
k i n e sA N O V Aw a sp e r f o r m e df o l l o w e db yp a i rw i s ec o m p a r i s o n sw i t h
control using the Dunnett’s test. For analysis of video data of the
percentage of mMSCs adhered, crawled and spread, unpaired T tests
were used to compare chemokine treatments with control.
Results
Murine Mesenchymal Stem Cell Interaction with TNFa-
Stimulated Endothelium under Shear Flow Conditions
Microslides were seeded with MAECs and stimulated with
TNFa (100 ng/ml) as described. MSCs were flowed through the
microslides at 0.1 Pa, which is a physiological flow rate relevant to
leukocyte recruitment in the postcapillary venules or the low shear
environments in the arterial circulation which are prone to
formation of atheroma. MSCs were observed for any interaction
with the endothelium. Over 4 minutes of mMSCs flowing through
the microslides there was no interaction of MSCs with the
endothelium. No mMSCs were observed to be rolling on or
adhered to the endothelial layer both after treating these cells with
and without TNFa. This assay was repeated with MAECs with
and without TNFa stimulation, together with or without the
additionofthechemokinesCXCL9,CXCL16,CCL20andCCL25
at 100 ng/ml for 30 minutes; these chemokines were chosen since
they are ligands for the chemokine receptors previously shown to be
present on mMSCs [17]. Again no mMSCs were seen to interact
with the endothelium after stimulation with any combination of
TNFa and/or chemokines (Video S1). The flow rate was slowed
down to less than half the speed, i.e. 0.15 ml/min (0.05 Pa, 0.5
dynes/cm
2), but mMSCs still did not roll on or adhere to the
endothelium in the presence or absence of chemokines. Similarly
when murine brain endothelial cells, bEnd.3cells, wereused instead
of MAECs there was no rolling or adherence of mMSCs to these
cells under flow conditions (data not shown).
Next mMSCs were added to MAECs which had been
stimulated with TNFa alone (100ng/ml for 16 hours) or TNFa
in the presence of CXCL9 (100 ng/ml for 30 min). The cells were
left under flow-free conditions for 10min, and then the flow was
started at 0.1 Pa (1 dyne/cm
2) for 2 hours. MSCs appeared
rounded and phase bright upon a background of endothelial cells
(Figure 1). When the flow was started, 76% of the MSCs remained
firmly adhered to the TNFa-treated endothelial cells whereas in
the presence of CXCL9 and TNFa 94% remained firmly adhered,
which was significantly more than in the absence of chemokine
(p=0.04) (Figure 2); the reminder of the MSCs detached and
flowed away. Over the next 2 hours of flow, of those that had
adhered 71% crawled on TNFa-treated endothelial cells whereas
94% crawled in the presence of CXCL9 and TNFa, amounting to
a significant increase compared to the absence of chemokine
(p=0.02) (Figure 2). Crawling behaviour was characterised by the
MSCs remaining phase bright and rounded in shape, undergoing
lateral movement on the endothelial surface and extending fine
microvillous processes (or filopodia) (Figure 1; videos S2 and S3).
These filopodia were rapidly moving and associated with the MSC
having a millipede-like movement. Quantitation revealed that
mMSCs crawled 2366 mm and 2162 mm in the presence of
TNFa and CXCL9/TNFa respectively prior to spreading (mean
6 standard error of 3 independent experiments in each case) and
there was no significant difference between these two values. In the
presence of TNF, 3767% of mMSCs crawled against the
direction of flow and 6068% crawled in the direction of flow.
With CXCL9/TNF, 6569% moved against the direction of flow
and 3669% in the direction of flow (data are means 6 standard
error of 3 independent experiments in each case). There was no
significant difference between these values, in terms of TNF and
CXCL9/TNF treatment and the direction of crawling.
Figure 1. Still images from flow assay video to illustrate
crawling of mMSCs on mouse aortic endothelial cells (MAECs).
MAECs were TNFa-activated, mMSCs added and left for 10 minutes.
Flow was then started and continued for 2 hours and video recordings
made. The direction of flow is shown by the large white arrow. A, shows
a low power image of TNFa-activated MAECs with adherent phase
bright MSCs immediately after commencing shear stress (from video
S2). B-F show detail of an MSC indicated in the top right of A. B is
immediately after commencing shear stress and C, D, E and F after 30,
60, 80 and 120 minutes of flow respectively. The asterisk is a reference
point to illustrate crawling of the MSC over the time period and by 120
minutes (F) the cell has stopped crawling, begun to spread and become
phase dark. Around the periphery of the MSC are examples of fine
phase-dark microvillous processes (or filopodia) (arrows) that extend
during crawling of the MSC on the endothelial surface. Data are extracts
of video S2 which is representative of 3 independent experiments. The
bars represent 100 mm in A and 20 mm in B-F.
doi:10.1371/journal.pone.0025663.g001
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podia were extended in several directions often giving the MSC a
stellate shape (Figure 3; video S3). 29% of the crawling MSCs spread
with TNFa-treated MAECs, whereas 70% of crawling MSCs spread
with TNFa and CXCL9-treated MAECs (Figure 4). This amounted
to a significant increase in the percentage of spread MSCs in the
presence of CXCL9 compared to its absence (p,0.001).
The influence of flow on the crawling and spreading of mMSCs on
MAECs was then examined. mMSCs were added to the endothelial
cells and left under flow-free conditions for 10 min. The flow was
started briefly for 15 seconds to remove non-adherent cells. It was
then stopped and the adhered cells videoed for 2 hours to image
crawling and spreading behaviour. In terms of crawling, only 3% of
adhered mMSCs crawled on TNFa-activated MAECs inthe absence
of flow, increasing to 8% with the addition of exogenous CXCL9
(Figure2).Thesevaluesweresignificantlylessthaninpresenceofflow
(p,0.001 in each case), amounting to 24- and 12-fold reductions
respectively. In terms of spreading, 8% of MSCs spread with TNFa-
treated MAECs in the absence of flow which was not significantly
different (p=0.08) than in the presence of flow (28%) (Figure 4).With
the addition of CXCL9, 7% of mMSCs spread in the absence of flow
which was significantly less than in the presence of flow (70%),
amounting to a 10-fold reduction (p,0.001) (Figure 4).
Murine Mesenchymal Stem Cell Migration across an
Endothelial Layer is Increased in Response to
Chemokines
In order to examine if the mMSCs transmigrated across
endothelial cells, MAECs were grown on the filters of transwells.
Chemotaxis assays were set up as described with 10ng/ml CCL20,
CCL25, CXCL9 or CXCL16, or medium alone, in the bottom
well after treatment of MAECs with murine TNFa. Three wells
were left untreated as a control. To work out the number of cells
per well which had migrated across the endothelium in the
transwell system, a standard curve of fluorescence against cell
number was set up, using some of the same population of mMSCs
that had been labelled with calcein for the assay. Each set of
conditions was set up in triplicate, and three fluorimeter readings
were taken for each well to calculate the number of cells which had
migrated through.
A significantly higher number of mMSCs migrated across the
MAEC layer stimulated with TNFa, into the bottom well, in
response to CXCL16 (mean of 143807 cells per well), CXCL9
(mean of 153083 cells per well), CCL20 (mean of 154894 cells per
well) and CCL25 (mean of 158640 cells per well), compared to
TNFa stimulated MAECs with no chemokine (mean of 91785
cells per well) or MAECs with no TNFa stimulation and no
chemokine (mean of 94868 cells per well) (Figure 5, P=,0.001 for
all four chemokines with TNFa, versus no chemokine with TNFa,
or media alone).
Analysis of Migrated mMSCs
The migrated and non-migrated mMSCs were also analysed by
flow cytometry for expression of the chemokine receptor
corresponding to the chemokine that was used in the assay. This
was in order to study if gene expression was altered as a result of
transmigration. The chemokine receptors CXCR3, CXCR6,
CCR6 and CCR9 were found to be down-regulated on the
Figure 2. The percentage of mMSCs that adhered and crawled
on MAECs. MAECs were TNFa-activated and incubated with or
without CXCL9. mMSCs were then added, left for 10 minutes and
media flowed over the MAECs for 2 hours and video recordings made
as in Figure 1 (clear bars). mMSCs were also treated the same except
that the flow was stopped during the 2 hour period (solid bars). Data
are means (6standard errors) of 3 independent experiments (with
passage number 7–9). *p,0.05 compared to the respective no
chemokine control. #p,0.001 compared to same treatment under
flow conditions.
doi:10.1371/journal.pone.0025663.g002
Figure 3. Still images from flow assay video to illustrate
spreading of mMSCs in contact with MAECs. MAECs were TNFa-
activated and incubated with CXCL9. mMSCs were then added, left for
10 minutes and media flowed for 2 hours and video recordings made.
A-D show images the same MSC on TNFa-activated MAECs in the
presence of exogenous CXCL9 (extracted from video S3). A, shows a
rounded phase bright MSC after 30 minutes of flow. B, the cell is
extending a pseudopod (arrow) after 60 minutes. C and D, the cell
spreads becoming phase–dark extending pseudopods in several
directions after 90 and 120 minutes respectively. Data are extracts of
video S3 which is representative of 3 independent experiments. Bar
represents 20 mm for each image.
doi:10.1371/journal.pone.0025663.g003
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of their mean fluorescence intensity (MFI) and percent positive
cells (Figure 6 and Table 1). Murine MSCs which had migrated in
response to CXCL16 were 20% positive for CXCR6 compared to
55% in the top well, and had an MFI of 10 compared to 20.
Murine MSCs which had migrated in response to CXCL9 were
46% positive for CXCR3 compared to 89% in the top well, and
had an MFI of 25 compared to 117. Murine MSCs which had
migrated in response to CCL20 were 53% positive for CCR6
compared to 91% in the top well, and had an MFI of 33 compared
to 198. Murine MSCs which had migrated in response to CCL25
were 51% positive for CCR9 compared to 88% in the top well,
and had an MFI of 46 compared to 97.
Discussion
The current study showed that mMSCs interact with MAECS
showing firm adhesion, and crawling and spreading behaviour,
which were all enhanced by CXCL9. These interactions occurred
when the mMSCs were applied to the endothelial cells, left under
shear–free conditions for several minutes and then the flow started.
However, under conditions of constant shear flow we observed no
capture or rolling of mMSCs on the surface of MAECs or bEnd.3
endothelial cells stimulated with TNFa, chemokines or both, and
at two different wall shear stresses (0.1 and 0.05 Pa (1 and 0.5
dynes/cm
2)). This is in contrast to leukocytes such as neutrophils
that show rolling behaviour in the same in vitro flow assay system
[35]. The lack of rolling of MSCs is probably related to the lack of
expression of L-selectin and the P- and E-selectin counterligands
glycoprotein ligand-1 (PSGL-1) and sialyl Lewis X carbohydrates,
reflecting the finding that MSCs are unable to bind functionally to
constructs of P- and E-selectin [13,25,36,37]. Such counterligands
are expressed on all leukocytes, and mediate the rolling phase of
the adhesion cascade by interacting with selectins on endothelial
cells [14]. Others have also shown a lack of rolling behaviour of
MSCs on stimulated and unstimulated human umbilical vein
endothelial cells (HUVECs) in vitro under flow conditions [37].
One study has shown rolling MSCs on HUVECs in vitro, however
rolling velocities were high, 100–500 mm/s at shear stress of
0.1–1.0 dynes/cm
2 [13,25]. For comparison, leukocytes typically
roll at around 5 mm/s at shear stresses of up to 4 dynes/cm
2 [38].
There are two potential mechanisms for how MSCs may
decelerate within the vasculature during the extravasation process
Figure 4. The percentage of mMSCs that spread in contact with
MAECs. MAECs were TNFa-activated and incubated with or without
CXCL9. mMSCs were then added, left for 10 minutes and media flowed
over the MAECs for 2 hours and video recordings made as in Figure 3
(clear bars). mMSCs were also treated the same except that the flow
was stopped during the 2 hour period (solid bars). Data are means
(6standard errors) of 3 independent experiments with MSCs (with
passage number 7-9). *p,0.05 compared to the respective no
chemokine control. #p,0.001 compared to same treatment under
flow conditions.
doi:10.1371/journal.pone.0025663.g004
Figure 5. Transendothelial migration of mMSCs in response to chemokines. Graph to show number of fluorescently labelled MSCs that
migrated to the bottom well through MAEC layers grown on the filters of transwell inserts. MAECs were treated with or without TNFa and in the
presence or absence of CXCL16, CXCL9, CCL20 and CCL25 (each at 10 ng/ml). Values represent means 6 standard errors of 3 independent
experiments and each experiment was performed in triplicate. *p,0.0001 compared to control in the presence of TNF and absence of chemokine
and p=0.0004 compared to control in the absence of TNF and chemokine.
doi:10.1371/journal.pone.0025663.g005
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physical interactions with narrower capillaries leading to arrest
and passive entrapment. It has been noted that when MSCs are
injected intravenously they can become trapped in organs such as
the lungs, even under normal conditions in the absence of tissue
damage or inflammation, and this has been attributed to their
large size [39]. Secondly, similar to leukocytes, MSCs may actively
tether and roll on the activated vasculature leading to arrest and
firm adhesion. Our results are in line with the first mechanism
suggesting that it is not an obligatory prerequisite to have
leukocyte-like rolling prior to arrest and firm adhesion. As long
as the MSCs are slowed or stationary for a period of time it
appears to be sufficient to enable chemokine presentation and firm
adhesion, followed by crawling and spreading.
There are several clinical situations when blood flow is stopped
for a period of time for the treatment of atherosclerosis. For
example this occurs during coronary artery bypass surgery and
angioplasty when a balloon catheter is inflated in the artery. In
stem cell trials for the treatment of atherosclerosis it is worth
noting that a period when the blood flow is stopped and then
restarted may not be detrimental to the recruitment of these cells.
In addition, deceleration of MSCs in the small vessels of the artery
wall (eg in the vasa vasorum) in arteriosclerosis may be sufficient
for recruitment of these cells.
In the current study stopping the flow for several minutes prior
to starting it resulted in shear-resistant arrest of the MSCs on the
endothelial cell surface. This resulted in virtually all of the MSCs
(94%) remaining attached in the presence of chemokine. It is
probable that integrins such as VLA-4 is involved in the firm
attachment since this has been shown to be expressed by MSCs
and to mediate adhesion to V-CAM on the endothelial surface
[25,26,28], although this may depend on the tissue source of the
MSCs [36]. The finding that CXCL9 enhances the firm adhesion
of mMSCs to MAECs suggests that this chemokine is presented to
the MSC resulting in stimulation of integrin activation and
increased affinity of this adhesion molecule for its endothelial
ligand. In this respect integrin activation is a classic role of
chemokines, enhancing the firm adhesion of leukocytes to the
endothelium [14].
In the case of leukocytes, they do not necessarily transmigrate at
the point of initial arrest but locomote laterally, or crawl, to
preferred sites of transendothelial migration [40]. Lymphocytes in
vitro extend filopodia and undergo millipede-like crawling on
endothelial cells which is enhanced by exogenous chemokine [41].
In the present study MSCs also extended fine microvilli or
filopodia and underwent millipede-like crawling, furthermore
exogenous CXCL9 increased the percentage of MSCs that
crawled. They were able to crawl against or with the direction
of flow, which has also been reported for neutrophils [42], and the
Figure 6. Migrated mMSCs show a lower level of chemokine receptor expression. Histogram plots to show chemokine receptor expression
on mMSCs in the top and bottom wells of transwells after transendothelial chemotaxis. Percent positive mMSCs and mean fluorescence intensity
(MFI) are shown for each plot. Line graphs are Ig controls and filled histograms show results with chemokine receptor antibodies. Data show a
representative experiment.
doi:10.1371/journal.pone.0025663.g006
Table 1. Down-regulation of chemokine receptors on mMSCs
in transwells after transendothelial migration.
CXCR6 CXCR3 CCR6 CCR9
Top well (%
positive cells)
55% 89% 91% 88%
Bottom well (%
positive cells)
20% 46% 53% 51%
Top well (MFI)




10 25 33 46
Data are obtained from Figure 6;
a= mean fluoresence intensity.
doi:10.1371/journal.pone.0025663.t001
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vitro, around 20 mm [40]. Following crawling, MSCs spread,
changing from a spherical morphology to a flattened often stellate
shape. In this respect spreading is also a feature of migrating
leukocytes [14,43]. Exogenous CXCL9 particularly increased the
numbers of MSCs that spread in comparison with the other
parameters measured. Spreading was characterised by the
extension of pseudopodia in multiple directions. These structures
resemble the plasmic podia which have also been described on
human MSCs interacting with cultured endothelial cells under
static conditions [27].
In the present study endothelial cells in the flow assay were pre-
treated with TNF which may up-regulate expression of their
adhesion molecules and chemokines. Addition of exogenous
CXCL9 increased MSC adherence, crawling and spreading on
endothelial cells, in comparison to its absence, showing a
significant effect of this chemokine. However, it cannot be ruled
out that endothelial-expressed chemokines may be having an effect
as well, so displacement of such chemokines by heparin for
example may have given a better indication of the role of CXCL9.
Interestingly, in the case of transwell migration experiments TNF
treatment alone of the same endothelial cells does not appear to be
having an effect on adhesion and transmigration since the number
of migrated MSCs is the same in the presence or absence of TNF.
Arrest of leukocytes on endothelial cells is enhanced by flow-
derived shear forces [44,45]. It is indicated that this is mediated by
shear enhancing the activation of integrins which occurs in
association with the action of chemokines. In the case of MSCs,
these cells were particularly sensitive to the effect of shear, when
the flow was stopped during the phases of crawling and spreading
there was a marked reduction in the numbers of MSCs showing
such behaviour. In the absence of flow the percentage of crawling
MSCs was negligible (3%) increasing to 71% in the presence of
flow, and this increased to 94% in the presence of flow and
chemokine. This indicates that flow is a major contributing factor
in addition to that of chemokine. Similarly spreading was
markedly increased by shear forces with the percentage of cells
showing this behaviour increasing from 7% to 70% in the presence
of chemokine. Therefore the influence of flow needs to be taken in
consideration in designing therapeutic strategies when MSCs are
administered in the circulation.
There have been many in vivo studies in disease models and
humans showing that MSCs administered into the circulation can
engraft into the affected tissues, although the efficiency may be
quite low [1,13]. For example this occurs following myocardial
infarction where MSC recruitment into the heart can result in
clinical benefit [1,46]. However, very few studies have examined
the transmigration of MSCs. Steingen et al [27] reported that
MSCs can transmigrate across non-activated endothelial mono-
layers via VCAM/VLA-4, but rather than undergoing complete
diapedesis, as observed for leukocytes, MSCs tended to integrate in
to the endothelial cell layer, possibly as embedded pericytes. The
current study shows that MSCs can fully transmigrate across the
endothelial cell layer, into the bottom well of transwells, and that
this is significantly enhanced by the presence of chemokines
CXCL9, CXCL16, CCL20 and CCL25. These chemokines were
chosen since they are the ligands for the receptors CXCR3,
CXCR6, CCR6 and CCR9 which were shown to be particularly
expressed on the mMSCs used in the present study [17]. The
chemokines showed specificity in their effects since in their absence
(no chemokine control), significantly less MSCs transmigrated. In
addition, TNF alone did not enhance MSC migration compared
to control further indicating the specificity of the chemokine
response. In our previous study [17] using standard Boyden-style
chemotaxis assays in the absence of endothelial cells CXCL9,
CXCL16, CCL20 and CCL25 (at 10 and 100 ng/ml) elicited a
migratory response using the same mMSCs, whereas CXCL12 did
not. This further showed specificity of the migratory responses of
mMSCs to chemokines.
The chemotactic responses of mMSCs in Boyden-style chambers
are comparatively sensitive, peaking between 10 and 100 ng/ml
and showing lack of response above and below these concentrations
[17]. In the case of CCL25, higher concentrations have been
required to stimulate chemotaxis (eg 1500 ng/ml) using other cells
types such as human Jurkat cells [47]. In the current transendothe-
lial migration study 10 ng/ml of chemokines was used leading to
significant effects on mMSC migration. This further suggests that
mMSCs are relatively sensitive to migratory stimulation by
chemokines although the effects of having endothelial cells may
also enhance migration compared to chemotactic filters.
In addition, following the adhesion and transmigration of MSCs
across endothelial cells gene expression is altered and chemokine
receptors are down-regulated. Ligand-induced down-regulation is
a well-documented feature of leukocyte chemokine receptors
occurring by receptor internalization and endocytosis [48]. The
down-regulation on MSCs suggests that once these cells have
migrated across the endothelium and into the tissue, chemokine
receptor expression may be reduced or a different spectrum of
chemokine receptors induced in the tissue environment, as
indicated for lymphocytes [49], influencing further positioning
within the tissue.
In conclusion the model derived from the current study has
aspects of both passive and active homing previously proposed for
MSCs [13]. Passive reduction of velocity or stasis of MSCs may
occur when they pass though narrow capillaries, this enables
chemokine presentation, integrin activation, arrest and firm
adhesion, crawling and spreading. The MSCs then follow a
directional cue given by immobilised chemokines to migrate into
the extravascular tissue. Since CXCR3 and CXCR6 are reported
to be important for T lymphocyte and monocyte recruitment to
atherosclerotic plaques [50,51], MSCs may be able use these
receptors to enter the lesion. Furthermore manipulating the
expression of these receptors on MSCs may enable increased
recruitment as a therapeutic benefit in the disease.
Supporting Information
Video S1 mMSCs flowing over TNFa stimulated
MAECs, with exogenous CXCL16 added, after 4 minutes
of continuous flow. There is lack of interaction of mMSCs with
the endothelial cell layer, with MSCs appearing as blurred
‘‘streaks.’’ The video is representative of 3 independent experi-
ments. Magnification 6200.
(MPEG)
Video S2 mMSCs interacting with TNFa stimulated
MAECs. MSCs were incubated with the endothelial cells for 10
minutes in the absence of flow. The flow was then started and
continued for 2 hours. The video shows adhered phase-bright
MSCs under flow that undergo crawling, extending numerous fine
microvilli that rapidly change shape on the endothelial surface.
Some of the MSCs then spread becoming phase-dark. The video is
representative of 3 independent experiments. Bar =200 mm.
(MPEG)
Video S3 mMSCs interacting with TNFa stimulated
MAECs with exogenous CXCL16 added. MSCs were
incubated with the endothelial cells for 10 minutes in the absence
of flow. The flow was then started and continued for 2 hours. The
Mesenchymal Stem Cell Migration
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25663video shows adhered MSCs under flow that undergo crawling when
phase-bright and then spreadingbecoming phase-dark. Thevideo is
representative of 3 independent experiments. Bar =200 mm.
(MPEG)
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